Alloplex is pleased to announce its participation in the US East Coast Immuno-Oncology Xchange to be held in Boston on May 23, 2023.
Our CEO, Frank Borriello, will be in attendance and participate in a number of round table discussions. Specifically, SUPLEXA therapeutic cells will be discussed in the new cellular modalities track. Our recently identified pharmacodynamic signature of activity should provide a concrete example of the use of biomarkers to advance cellular therapy development.
HubXchange’s Immuno-Oncology Xchange East Coast 2023 brings together executives from pharma and biotech to address and find solutions to the key issues faced in developing immuno-oncology therapies, through a series of roundtable discussions.
https://www.hub-xchange.com/immuno-oncology-xchange-east-coast-2023/
To request interviews, high res images or other materials, media are asked to:
Email: media@alloplexbio.com
Attn: Lesley White, Alloplex Australia
For media requests on deadline during USA Eastern hours, please call: +1-781-281-2013
